HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, July 8, 2019 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device manufacturer Atomo Diagnostics today announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO...

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow...

Sydney, Australia and Seoul, South Korea – 23 January 2018 | Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets. ...

Sydney, Australia, 7 December 2017 | Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources. Atomo HIV Self...